Jilin Aodong Pharmaceutical Group Co Ltd

Jilin Aodong has released its 2026 semi-annual report, showing net profit attributable to the parent company up nearly 60% year-on-year, with significant results from its dual-driven strategy of industry and finance. As of the end of June, the company's total assets reached 36.049 billion yuan, net assets stood at 31.989 billion yuan, and the asset-liability ratio was only 10.66%. In the first half of the year, operating revenue was 1.031 billion yuan, down 8.47% year-on-year, but net profit attributable to the parent reached 2.05 billion yuan, a sharp increase of 59.96%, mainly due to a substantial rise in investment income. As the largest shareholder of GF Securities, investment income for the period was 2.173 billion yuan, up 80.17% year-on-year. On the pharmaceutical main business side, revenue from the traditional Chinese medicine segment was 658 million yuan, accounting for 63.78% of total revenue, while the chemical pharmaceuticals, chain pharmacy, and broader health segments also developed steadily. The company continues to deepen the integration of industry and finance, having established five industrial funds with GF Xinde, focusing on investments in areas such as biopharmaceuticals.

Jilin Aodong has released its first-half earnings forecast, expecting net profit to reach between 1.922 billion and 2.179 billion yuan, representing a year-on-year increase of 50.00% to 70.00%. According to statistics from Securities Times Data Treasure, the stock closed at 17.89 yuan today, up 2.23%, with a daily turnover rate of 1.31% and a trading volume of 276 million yuan. In terms of capital flows, main funds saw a net inflow of 9.9796 million yuan today, while over the past five days there was a net outflow of 12.8837 million yuan. The latest margin trading balance stood at 1.459 billion yuan, with the financing balance at 1.451 billion yuan, down 0.70% from the previous trading day, and the financing balance has cumulatively decreased by 1.04% over the past five days.